Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.28−0.22 (-2.37%)
Close on Nov 17, 2026Market cap $596.89MP/E –Yield –
Cullinan Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cullinan Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $0, down 100.0% year over year. For fiscal 2022 it was $0, down 100.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $18.94M | – |
| FY2020 | Dec 31, 2020 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | -100.0% |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $18.94M | – |
See a number that looks wrong?